Drug Profile
Ocedurenone - Novo Nordisk
Alternative Names: KBP-5074; NN-6023Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator KBP Biosciences
- Class Antihypertensives; Small molecules
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal hypertension
Most Recent Events
- 16 Oct 2023 Novo Nordisk acquires ocedurenone from KBP Biosciences
- 07 Sep 2023 Pharmacokinetics and adverse events data from a phase I trial in Renal-hypertension (In volunteers) presented at theHypertension Scientific Session 2023(HTN-2023)
- 06 Jan 2023 Adverse events and pharmacokinetics data from a phase I trial in hepatic impairment released by KBP Biosciences